Oric Pharmaceuticals (NASDAQ:ORIC) Coverage Initiated at Stifel Nicolaus

Stock analysts at Stifel Nicolaus began coverage on shares of Oric Pharmaceuticals (NASDAQ:ORIC) in a report issued on Friday. The firm set a “buy” rating and a $14.00 price target on the stock. Stifel Nicolaus’ target price indicates a potential upside of 77.48% from the company’s previous close.

A number of other analysts have also issued reports on ORIC. HC Wainwright reissued a “buy” rating and issued a $25.00 price target on shares of Oric Pharmaceuticals in a research report on Monday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oric Pharmaceuticals in a research note on Tuesday, April 21st. Oppenheimer reiterated an “outperform” rating and issued a $15.00 target price on shares of Oric Pharmaceuticals in a research report on Tuesday, February 24th. Citigroup decreased their target price on shares of Oric Pharmaceuticals from $17.00 to $16.00 and set a “buy” rating for the company in a research note on Tuesday, May 5th. Finally, Benchmark reaffirmed a “buy” rating on shares of Oric Pharmaceuticals in a research note on Monday. Fourteen analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $18.92.

Oric Pharmaceuticals Stock Up 0.9%

Shares of Oric Pharmaceuticals stock traded up $0.07 during midday trading on Friday, hitting $7.89. The company’s stock had a trading volume of 156,892 shares, compared to its average volume of 1,797,276. Oric Pharmaceuticals has a 1-year low of $7.23 and a 1-year high of $14.93. The firm has a market capitalization of $816.57 million, a P/E ratio of -5.47 and a beta of 1.04. The stock has a 50-day simple moving average of $9.01 and a 200-day simple moving average of $10.18.

Oric Pharmaceuticals (NASDAQ:ORIC) last posted its quarterly earnings results on Monday, May 4th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.03). As a group, sell-side analysts predict that Oric Pharmaceuticals will post -1.43 earnings per share for the current year.

Institutional Trading of Oric Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in ORIC. Federation des caisses Desjardins du Quebec boosted its holdings in shares of Oric Pharmaceuticals by 100.0% during the 4th quarter. Federation des caisses Desjardins du Quebec now owns 4,000 shares of the company’s stock worth $33,000 after buying an additional 2,000 shares during the period. Assetmark Inc. acquired a new position in Oric Pharmaceuticals during the 3rd quarter worth $37,000. Caitong International Asset Management Co. Ltd boosted its holdings in Oric Pharmaceuticals by 184.4% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 4,528 shares of the company’s stock valued at $37,000 after acquiring an additional 2,936 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Oric Pharmaceuticals by 26.0% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,732 shares of the company’s stock worth $39,000 after purchasing an additional 977 shares during the last quarter. Finally, Russell Investments Group Ltd. bought a new stake in Oric Pharmaceuticals during the 3rd quarter valued at approximately $60,000. Institutional investors and hedge funds own 95.05% of the company’s stock.

Oric Pharmaceuticals Company Profile

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.